Emergence of ICOS hi CD4 T Cells is Associated with Tumor Reduction, Progression-Free Survival, and Overall Survival in Advanced Cancer Patients Treated with Vopratelimab, an ICOS AgonistTuesday, 29 October 2019 at 08:30 Add to Calendar ▼2019-10-29 08:30:002019-10-29 09:30:00Europe/LondonEmergence of ICOS hi CD4 T Cells is Associated with Tumor Reduction, Progression-Free Survival, and Overall Survival in Advanced Cancer Patients Treated with Vopratelimab, an ICOS AgonistImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com Vopratelimab is an ICOS agonist antibody intended to stimulate primed CD4 T effector cells. In the ICONIC trial, peripheral T cell phenotyping demonstrated emergence of an ICOShi subset of activated CD4 T effector cells associated with tumor reductions and improved PFS and OS, with expansion of peripheral T cell receptor clones found in the original matched archival tumor. Future development focuses on settings in which ICOShi CD 4 T effector cells are primed to respond to vopratelimab. |